Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Is Rising Today

By Brian Feroldi - Feb 21, 2018 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rally after management gives a presentation at an investor conference. Here's what investors need to know.

What happened

In response to the company's presentation at the RBC Capital Markets 2018 Global Healthcare Conference, shares of TransEnterix (ASXC 2.64%), a medical device maker focused on robotic surgery, rose as much as 12% in afternoon trading on Wednesday. The rally has since cooled off, but shares are still up about 7% as of 3:25 p.m. EST.

So what

TransEnterix CEO Todd Pope has been presenting at a handful of investor conferences in recent weeks in an effort to build up support for his company's stock. Today's presentation appears to have done the trick. 

Durig the presentation, CEO Pope talked in general about the company's commercialization strategy and highlighted a few recent successes that it has had in international markets. He also touched on the company's product roadmap, competition, and the opportunities that lie ahead.  

Traders clearly liked what CEO Pope had to say, which is why shares rose today.

Microphone in front of group

Image source: Getty Images.

Now what

2018 is going to be a pivotal year for TransEnterix. The pressure is on for the company to show as much commercial traction as possible for its Senhance system. On that front, investors recently learned that the company expects to recognize revenue from two Senhance sales in the current quarter. What's more, the company just submitted for a label expansion claim in the U.S. that should more than double its addressable market opportunity if it gets the green light.

Will TransEnterix's small commercial team be able to wrestle away market share from Intuitive Surgical? It's possible, but I still think that the situation is far too dicey to put any capital at risk. That's why my plan is to watch this story play out from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.39 (2.64%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.